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Abstract
 
The precursor origin of T helper (Th) cell subsets in vivo has been difficult to study and re-
mains poorly investigated. We have previously shown that chronic administration of soluble
protein antigen induces selective development of antigen-specific CD4 Th2 cells in genetically
predisposed mouse strains. To analyze the origin of effector T cells in this model, we designed
a competitive polymerase chain reaction–based approach to track public BV-J rearrangement
expressed by CD4 T cells specific for hen egg white lysozyme (HEL) in BALB/c mice. We
show that public T cell clones are predominantly associated with type 1 or 2 effector Th cells
recovered after primary immunization in complete or incomplete Freund’s adjuvant, respec-
tively. Conversely, continuous administration of soluble antigen, which induces strong mem-
ory Th2 response, is associated with a dose-dependent reduction of public clone size by a
mechanism resembling clonal anergy. Thus, soluble HEL–induced Th2 cells do not express the
public complementarity determining region 3 motifs characteristic of immunogenic challenge
in the presence of adjuvant. These results demonstrate that there are multiple pathways of in-
duction of Th2 responses depending on the condition of antigen exposure in vivo, i.e., clonal
immune deviation versus recruitment of a different pool of precursor cells.
Key words: clonal expansion • antigen-speciﬁc public repertoire • CD4 T cell subsets • 
chronic antigen stimulation • clonal anergy
 
Introduction
 
CD4 T cells have been subdivided into different subsets ac-
cording to their cytokine profiles (1–3). Mouse Th1 cells
produce IL-2, IFN-
 
g
 
, and TNF-
 
b
 
, whereas Th2 cells se-
lectively secrete IL-4, IL-5, IL-10, and IL-13 (4). Th1 and
Th2 cells not only differ by their cytokine secretion pat-
terns but also by their effector functions in vivo, resulting
in deleterious or protective immunity depending on the
pathogens (5). To explain the Th1/Th2 differentiation par-
adigm, it has been initially hypothesized that the two sub-
sets could be derived from either two different pools of
precursor cells or a common precursor (6). Data obtained
from limiting dilution analysis (7, 8) and studies in TCR-
transgenic mice (9, 10) have clearly shown that naive CD4
T cells have the capacity to differentiate into either Th1 or
Th2 effector cells and that this process is critically influ-
enced by the cytokine milieu during the initial phase of T
cell activation (11). Among cytokines, IL-12 and IL-4 have
been shown to play a decisive role by driving the polariza-
tion of T cell responses toward the Th1 or Th2 phenotype,
respectively (11–13).
To understand the mechanisms that govern the preferen-
tial growth and differentiation of normal CD4 T cell sub-
sets in vivo, we have designed an immunization protocol
that selectively induces Ag-specific Th2-type immune re-
sponses in BALB/c mice (14). Continuous administration
in normal and 
 
b
 
2 microglobulin–deficient BALB/c mice
of any soluble protein Ag followed by immunization with
the same Ag in adjuvant induces the selective development
of Ag-specific Th2 cells, which depends on the production
of endogenous IL-4 (14). Whereas Th1 cell unresponsive-
ness is observed in all strains tested after soluble Ag admin-
istration, Th2 development depends on a non-MHC–
linked genetic polymorphism and is predictive of disease
outcome after 
 
Leishmania major
 
 infection (15). Because in-
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hibition of Th1 cells in this experimental model appears to
be independent of induction of Th2 responses, we postu-
lated that both populations may arise from different precur-
sors in vivo. However, studying T cell responses to various
Ag challenges in vivo is limited by the fact that the fate of
Ag-specific T cells cannot be easily followed. We took ad-
vantage of the hen egg white lysozyme (HEL)
 
1
 
-specific T
cell responses in BALB/c mice, mainly directed against two
epitopes of the protein that involve public TCR V
 
b
 
 reper-
toire usage in CD4 T cells specific for each determinant
(16, 17). These public repertoires, found in every mouse,
are characterized by specific BV-J rearrangements with
conserved junctional sequences. Such characteristics al-
lowed us to design molecular probes to follow and quantify
HEL-reactive CD4 T cells bearing these particular CDR3
motifs.
In this paper, we analyze the clonal size and phenotype
of public CDR3–bearing CD4 T cells after administration
of the HEL protein either in adjuvant or soluble form to
BALB/c mice. We show that continuous administration of
low doses of soluble HEL induces a reduction of CD4 T
cells expressing the public CDR3 motifs specific for both
subdominant and dominant HEL epitopes, which can be
correlated with downregulation of Th1 responsiveness.
Therefore, the Th2 response that develops in these mice is
not due to immune deviation of lymphocytes bearing the
public CDR3 motifs toward IL-4–producing cells. This is
not due to the incapacity of T cells that expressed the pub-
lic rearrangements to develop along the Th2 pathway, as
they are found in IL-4–producing cells from mice primed
with HEL in IFA (HEL–IFA). Taken together, our data
support the conclusion that public repertoire expression in
polarized Th cell subsets is determined by the mode of pro-
tein Ag administration, suggestive that Th1 and Th2 cells
originate from different precursor populations after in vivo
priming.
 
Materials and Methods
 
Mice.
 
BALB/c (H-2
 
d
 
) mice were purchased from Centre
d’Elevage R. Janvier and maintained in our animal facilities un-
der pathogen-free conditions. 2–3-mo-old female mice were
used in all experiments.
 
Ags and Immunization.
 
HEL was obtained from Sigma
Chemical Co. HEL peptides (purity
 
 .
 
85%) were purchased from
Neosystem. Mini-osmotic pumps (Alzet 2001; Alza Corp.) were
implanted subcutaneously as previously described (14). 12 d after
pump implantation, mice were immunized subcutaneously into
the hind foot pads with 50 
 
m
 
g of HEL emulsified in IFA or CFA
containing H37Ra mycobacterium (Difco Labs., Inc.). Draining
popliteal LNs were removed 8–9 d after immunization.
 
T Cell Hybridomas.
 
The BV8S2-J1S5 2E8 hybridoma, spe-
cific for HEL 107–116/I-E
 
d
 
 antigenic complexes, was obtained as
previously described from HEL–CFA-immunized BALB/c mice
(18). The 2E8 V
 
b
 
 chain was sequenced as described elsewhere
(16). The nucleotide sequence of the junctional region was iden-
 
tical to the previously published sequence of C6.2 T cell hybrid-
oma (16), except that the first glycine codon in the CDR3 was
GGT instead of GGG. The BV8S2-J2S7 T cell hybridoma LC21,
specific for the HEL 12–25/I-A
 
d
 
 epitope, has been described
elsewhere (17). The TCR 
 
b
 
 chain CDR3 regions of these two
hybridomas were used to generate competitor plasmids as de-
scribed below.
 
T Cell Assays.
 
For cytokine production analysis, popliteal
LN cells (LNCs), undepleted or depleted of CD8
 
1
 
 cells, were
cultured at 5 or 6 
 
3
 
 10
 
5
 
 cells/well in 96-well culture plates (Co-
star Corp.) in synthetic HL-1 medium (HYCOR) supplemented
with 2 mM 
 
l
 
-glutamine (GIBCO BRL) and 50 
 
m
 
g/ml gentami-
cin (Sigma Chemical Co.) with the indicated Ag concentrations.
Cultures were incubated for 3 d in a humidified atmosphere of
6% CO
 
2
 
 in air. Supernatants from replicate cultures, usually three
to four wells, were collected after 72 h and pooled for cytokine
analysis. LNCs were depleted of CD8 cells by sequential incuba-
tion with KT1.5 mAb (19) culture supernatant and M-450 anti–
rat IgG Dynabeads (Dynal), followed by magnetic cell separation.
After 6 d of culture, 2 
 
3
 
 10
 
5
 
 CD4
 
1
 
 T cells, isolated as described
below, were stimulated with 3 
 
3
 
 10
 
5 
 
syngeneic spleen cells and
Ag in complete medium. Complete medium was RPMI 1640
supplemented with 10% FCS (ATGC Biotechnologie), 1% pyru-
vate, 1% nonessential amino acids, 1% 
 
l
 
-glutamine (GIBCO
BRL), 50 
 
m
 
M 2-ME, and 50 
 
m
 
g/ml gentamicin (Sigma Chemi-
cal Co.).
 
Cytokine Assays.
 
IFN-
 
g
 
 and IL-4 were quantified by sand-
wich ELISA as previously described (14). For IFN-
 
g
 
, polyvinyl
microtiter plates (Falcon 3912) were coated with 100 
 
m
 
l of AN-
18.17.24 mAb (20) in carbonate buffer. After blocking, samples
(50 
 
m
 
l/well) diluted in test solution (PBS containing 5% FCS and
1 g/liter phenol) were incubated together with 50 
 
m
 
l of peroxi-
dase-conjugated XMG1.2 mAb (2). After overnight incubation at
4
 
8
 
C, bound peroxidase was detected by 3,3
 
9
 
-5,5
 
9
 
-tetramethyl-
benzidine (Fluka Chemie AG) after blocking with 50 
 
m
 
l of 1N
H
 
2
 
SO
 
4
 
, and absorbance was read at 450 nm with an automated
microplate ELISA reader (Emax; Molecular Devices). For IL-4
determination, sandwich ELISA was performed with paired
mAbs, all purchased from PharMingen. Cytokines were quanti-
fied from two to three titration points using standard curves gen-
erated by purified recombinant mouse cytokines, and results were
expressed as cytokine concentration in nano- or picograms per
milliliter. Detection limits were 15 pg/ml for IFN-
 
g
 
 and IL-4.
 
Flow Cytometric Analysis of Intracellular Cytokine Synthesis.
 
LNCs were cultured as described above with 10 
 
m
 
M HEL. After
3 d of culture, cells were harvested, washed, and cultured for an
additional 3 d in complete medium. Living cells separated on
Ficoll gradient were resuspended at 10
 
6
 
 cells/ml and stimulated
with PMA (50 ng/ml; Sigma Chemical Co.) and ionomycin (0.5
 
m
 
g/ml; Sigma) for 4 h at 37
 
8
 
C, with 10 
 
m
 
g/ml of brefeldin A
(Sigma) added for the last 2 h. Cells were harvested, washed, and
stained using biotinylated GK1.5 anti-CD4 mAb (PharMingen),
followed by streptavidin–Cy-Chrome (PharMingen). At this
step, cells were fixed with 2% paraformaldehyde (Fluka Chemie
AG). Intracytoplasmic staining was performed as previously
described (21). After washing and 10-min incubation in 0.5% sa-
ponin medium, cells were incubated for 30 min at room tempera-
ture with the appropriate concentration of FITC- or PE-
conjugated, cytokine-specific mAb. The following mAbs were
used: PE–11B11 anti–IL-4 (PharMingen), FITC–JES5-16E3
anti–IL-10 (PharMingen), and FITC-labeled XMG1.2 anti–IFN-
 
g
 
(2). Cells were washed twice with saponin buffer and subse-
quently with PBS/FCS in the absence of saponin to allow mem-
 
1
 
Abbreviations used in this paper:
 
 DCs, dendritic cells; HEL, hen egg white
lysozyme; LNCs, lymph node cells. 
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brane closure. Data were collected on 2 
 
3
 
 10
 
4 
 
CD4
 
1
 
 T cells on
an XL Coulter cytometer (Coultronics), and results were ana-
lyzed using CELLQuest™ software (Becton Dickinson).
 
CD4
 
 
 
T Cell Isolation and FACS
 
®
 
 Sorting.
 
After 4 or 6 d of
culture, CD4
 
 
 
T cells were isolated by negative depletion using
M-450 anti–rat IgG magnetic beads (Dynal). In brief, cells were
washed and incubated for 30 min on ice with a cocktail of the
following mAbs: KT1.5 anti-CD8, RA3-3A1 anti-B220, and
M5-114 anti–MHC class II. After washing and incubation with
M-450 anti–rat IgG beads under agitation, CD4
 
1
 
 T cells were
purified by magnetic depletion. The purity of the negatively se-
lected CD4
 
1
 
 T cells controlled by flow cytometric analysis after
staining with FITC–GK1.5 anti-CD4 was 
 
z
 
95%.
For the detection of HEL-specific TCR 
 
b
 
 chain rearrange-
ment in T helper subsets, purified CD4
 
1
 
 T cells were stained for
intracellular cytokine synthesis as described above and sorted us-
ing an Elite Coulter cell sorter (Coultronics). Sorted cells, usually
0.5–1 
 
3 
 
10
 
6
 
, were pelleted, and DNA was extracted using the
Simple Nucleic Acid Preparation (S.N.A.P) whole blood DNA
isolation kit (Invitrogen BV).
 
TCRB Repertoire Analysis. 
 
The technique of repertoire
analysis with Immunoscope has been described elsewhere (22).
Total RNA was extracted from purified CD4 T cells using the
TRIzol procedure (GIBCO BRL); cDNA was synthesized us-
ing an oligo(dT)
 
17
 
 primer, murine moloney leukemia virus re-
verse transcriptase (Boehringer Mannheim), in the provided
buffer and RNasin (Promega Corp.). PCR run to saturation
was carried out in 50-
 
m
 
l reaction volume containing 2 U of
Taq polymerase (Promega Corp.), 2.5 mM MgCl
 
2
 
, 0.20 mM
dNTP, 0.5 
 
m
 
l of each primer, and cDNA template in the pro-
vided buffer. Oligonucleotides for repertoire analysis have been
described previously (17, 22, 23), except: BC130, 5
 
9
 
-TGCCT-
GAGCAGCCGCCTGAG-3
 
9
 
; BC145, 5
 
9
 
-CACTGATGTTCT-
GTGTGACAGGTTT-3
 
9
 
; BV8S2del, 5
 
9
 
-CATTATTCATA-
TGGTGCTGGCATGAGAAAGGAGAT-3
 
9
 
; and BC130del,
5
 
9
 
-TGCCTGAGCAGCCGCCTGAGGGTCTCACCTTCT-
GGC-3
 
9
 
. 40 rounds of amplification, each consisting of 1 min at
94
 
8
 
C, 1 min at 60
 
8
 
C, and 1 min at 72
 
8
 
C, were performed in a
9600 Perkin-Elmer thermocycler (Perkin-Elmer Applied Bio-
systems). In similar conditions, run-off reactions were performed
on 2 
 
m
 
l of PCR product with a single Fam-labeled primer
(CDR3, BJ1S5, or BC specific) at a final concentration of 0.1
 
m
 
M. 10-
 
m
 
l final volumes were subjected to one to three cycles
depending on PCR yield. 2-
 
m
 
l volumes of run-off products
were run on a 6% polyacrylamide 8 M urea gel in an auto-
mated 373A DNA sequencer (Perkin-Elmer Applied Biosys-
tems), together with size standard. The intensity of the various
bands was then recorded and analyzed with Immunoscope soft-
ware. To test the presence of the public rearrangement on the
DNA of Th subsets isolated by cell sorting, semiquantitative
PCRs were performed using AmpliTaq Gold™
 
 
 
DNA poly-
merase (Perkin-Elmer ABI) and the above-mentioned primers.
PCR products were analyzed on 2% agarose gel stained with
ethidium bromide. Specificity was confirmed by run-off reac-
tions as above.
 
Public Clone Quantification.
 
To estimate the frequency of
CD4
 
1
 
 T cells bearing clonotypic rearrangements, we used a fully
quantitative PCR protocol, already described (22). In brief, it
consists of the coamplification with the same primers of the
cDNA mixed with a known number of copies of a competitor
plasmid in which a 4-bp deletional specific sequence has been in-
tegrated. cDNA from LC21 (HEL 12–25/I-A
 
d
 
) and 2E8 (HEL
107–116/I-E
 
d
 
) T cell hybridomas bearing public CDR3 BV8S2-
J2S7 and BV8S2-J1S5, respectively, were amplified with
BV8S2del containing a 4-bp deletion and BJ-specific primers.
The shortened BV8S2-J1S5 and BV8S2-J2S7 clonotypic se-
quences were then integrated into the plasmid pCR
 
®
 
2.1-TOPO
using a TOPO TA cloning kit (Invitrogen Corp.). The recombi-
nant clones with the deletion were screened by sequencing. The
number of copies was estimated by OD determination. Aliquots
of cDNA of interest and of competitor plasmid were amplified
with BV8S2- and BJ-specific primers and then subjected to run-
off reactions with primers specific for the public CDR3 motifs
BV8S2-J2S7
 
HEL 12–25
 
 (HEL 12–25/I-A
 
d
 
–specific TCR 
 
b
 
 chain
public rearrangement) and BV8S2-J1SS
 
HEL 107–116
 
 (HEL 107–
116/I-E
 
d
 
–specific TCR 
 
b
 
 chain public rearrangement). Using
the same procedure as for the repertoire analysis, the ratio of in-
tensity of the two bands was plotted as a function of the number
of copies of standard plasmid introduced before amplification. A
regression calculation was performed to determine the equiva-
lence point (ratio 
 
5 
 
1), and thus the number of cDNA copies of
the given gene before amplification. For normalization, the num-
ber of TCR 
 
b
 
 chain copies was quantified in the same samples
using the same procedure (24). To generate the competitor C
 
b
 
plasmid, PCR products obtained using the BC130del and BC145
primers specific for a conserved region of C
 
b
 
1 and C
 
b
 
2 genes
were cloned and screened as above. Run-off reactions were per-
formed using the Fam-labeled BC 5
 
9
 
-TTGTCCTCCTCT-
GAAAGCCCATGG-3
 
9
 
 primer. Data were expressed as ratio of
public CDR3 over TCR BC mRNA copies.
 
Results
 
Phenotype and Specificity of Soluble HEL–induced Th2
Cells.
 
As previously shown, the continuous administra-
tion of soluble HEL to BALB/c mice results in the selec-
tive expansion of Ag-specific Th2 cells after subsequent in
vivo challenge with Ag in CFA (14, 15). After HEL restim-
ulation in vitro
 
,
 
 immune LNCs from soluble Ag–treated or
control BALB/c mice were analyzed at the single-cell level
for the intracellular production of IFN-
 
g
 
, IL-4, and IL-10.
Results in Fig. 1 A show that IL-4–producing CD4 T cells
selectively expand in mice implanted with HEL-containing
mini-osmotic pumps but not in control untreated BALB/c
mice. Among the IL-4–producing Th2 cells, 25% coex-
press IL-10 (Fig. 1 A). Conversely, HEL-specific CD4 T
cells that expand in HEL–CFA-immunized mice exhibit
mainly a Th1 phenotype, as shown by their capacity to se-
crete IFN-
 
g
 
.
In BALB/c mice, HEL-specific T cells are mainly di-
rected against a dominant epitope included in the HEL se-
quence 107–116 presented by I-E
 
d
 
 molecules (25). A sub-
dominant epitope, included in the HEL sequence 12–25,
has also been characterized that is restricted by I-A
 
d mole-
cules (17, 26). To analyze the specificity of Th2 cells, im-
mune LNCs from control or soluble HEL–treated BALB/c
mice were cultured with HEL for 6 d and then restimu-
lated with the synthetic peptides HEL 12–27 and HEL
103–117. As shown in Fig. 1 B, an opposite cytokine pro-
file is observed between the two groups of mice, indicating
that both Th1 and soluble Ag–induced Th2 cells recognize
the dominant and subdominant epitopes of the HEL pro-686 Different Origin of T Helper Type 2 Cells In Vivo
tein. Using a set of overlapping HEL peptides as described
elsewhere (14), no other reactivity could be defined (data
not shown).
The Public BV8S2-D1-J1S5 Rearrangement Is Associated
with the Th1 Phenotype in HEL–CFA-immunized BALB/c
Mice. It was previously shown that the T cell response
against the immunodominant HEL 107–116 epitope in
H-2d mice involves a public BV8S2-J1S5 repertoire found in
all animals with a specific CDR3 amino acid sequence,
GTGNNQAP (16). Immune LNCs from HEL–CFA-
primed mice secrete IFN-g in response to both HEL pro-
tein and HEL 103–117 peptide. To analyze whether these
IFN-g–producing cells express the public rearrangement,
we analyzed the presence of the public CDR3 motif
(BV8S2-J1S5HEL 107–116) on the DNA of HEL-specific CD4
T cells sorted on the basis of intracellular expression of
IFN-g. As shown in Fig. 2 A, DNA was extracted from
highly purified (.95%) IFN-g2 and IFN-g1 CD4 T cells
from LNCs restimulated in vitro as described in Fig. 1 A
and subjected to PCR using BV8S2- and BJ1S5-specific
primers. As shown in Fig. 2 B, the rearranged BV8S2-J1S5
products are preferentially amplified from the DNA ex-
tracted from IFN-g1 but not IFN-g2 CD4 T cells. Fig. 2
C shows the run-off reaction performed with CDR3-spe-
cific primers, demonstrating that the public CDR3 BV8S2-
J1S5HEL 107–116 motif is mainly expressed in IFN-g–produc-
ing CD4 T cells.
Induction of Th1 Unresponsiveness Correlates with a Reduced
Clonal Expansion of Public BV8S2-J1S5HEL 107–116 CD4 T
Cells in Soluble HEL–treated Mice. We next tested the ef-
fect of pretreatment with a wide dose range of soluble HEL
on the expression of the public rearrangement in HEL-spe-
cific CD4 T cells. Using the PCR-based approach Immu-
noscope, we analyzed the CDR3 size distribution of TCRs
bearing the BV8S2-J1S5 rearrangement as previously de-
scribed (16). As shown in Fig. 3 A, the CDR3 size distri-
bution among all BV8S2-bearing cells gives a set of seven
peaks, each separated by three nucleotides in control and
soluble HEL–injected mice. Conversely, a major expansion
with a CDR3 size of eight amino acids is observed with
BJ1S5 and public CDR3–specific primers in control ani-
mals immunized with HEL–CFA (Fig. 3 A). Interestingly,
continuous administration of soluble HEL is associated
with an increased heterogeneity in the CDR3 size in this
BV-J combination due to a diminished expression of the
BV8S2-J1S5HEL 107–116 public rearrangement. Data from
four individual mice per group are summarized in Fig. 3 B,
where CDR3 BV8S2-J1S5HEL 107–116–specific products are
expressed as percent of the sum of the BV8S2-BC peaks.
Therefore, continuous administration of low dose soluble
Figure 1. IFN-g– and IL-4–producing
CD4 T cells share common specificity.
Popliteal LNCs from control or soluble Ag
(HEL-pump)–treated BALB/c mice were
stimulated with HEL (10 mM) in vitro. (A)
After 6 d of culture, living cells were re-
stimulated with PMA and ionomycin dur-
ing 4 h in the presence of brefeldin A dur-
ing the last 2 h. Intracytoplasmic staining
for the indicated cytokines was performed
and analyzed on CD4 T cells. (B) To ana-
lyze the reactivity against HEL 12–25 and
HEL 103–117 epitopes, cells (105 per well)
were stimulated with synthetic peptides (10
mM) in the presence of irradiated syngeneic
splenocytes (3 3 105 per well). After 48 h,
IFN-g and IL-4 production was deter-
mined by ELISA in culture supernatants.
Figure 2. The public repertoire BV8S2-J1S5
specific for the dominant I-Ed–restricted HEL 107–
116 determinant is associated with IFN-g–produc-
ing cells. (A) After 6 d of in vitro stimulation, puri-
fied CD4 T cells from HEL–CFA-immunized mice
were stained for intracytoplasmic synthesis of IFN-g
and IL-4 as described in Fig. 1 and isolated by
FACS® as indicated. (B) Semiquantitative PCR for
public rearrangement BV8S2-J1S5, normalized on
constant region BC gene amplification, was per-
formed on DNA from whole CD4, IFN-g2, and
IFN-g1 cells. (C) Run-off reactions were per-
formed on PCR products with a CDR3-specific
fluorescent primer to confirm the presence of
BV8S2-J1S5HEL 107–116–specific sequence. Results
are representative of three experiments performed.687 Foucras et al.
HEL results in a strong reduction of Ag-specific T cells ex-
pressing the public CDR3 BV8S2-J1S5HEL 107–116 (Fig. 3 B),
which can be correlated with the downregulation of Th1
response but not with the expansion of IL-4–producing
cells (Fig. 3 C).
Induction of Th1 Cell Unresponsiveness by Soluble Ag Ad-
ministration Correlates with a Reduction of the Clonal Size of
Public Clones Specific for Both Dominant and Subdominant
HEL Epitopes. The dominant 107–116 and subdominant
12–25 HEL epitopes have been shown to exhibit different
requirements for Ag processing and presentation (17, 27).
Therefore, we next tested whether T cells specific for these
two determinants were similarly affected by systemic HEL
administration. As has been shown for 107–116/I-Ed–reac-
tive T cells, a public rearrangement, BV8S2-J2S7, charac-
terized by a conserved junctional sequence GDRLG-
GYEQ, has been identified in CD4 T cells specific for
HEL 12–25/I-Ad complexes (17). To quantify by competi-
tive PCR analysis the clonal size of CD4 T cells expressing
the two public CDR3 motifs, we designed two internal
standard DNA plasmids that contain the TCR-b sequence
corresponding to the public CDR3 motifs BV8S2-J1S5HEL
107–116 and BV8S2-J2S7HEL 12–25 with a four-nucleotide de-
letion in the BV8S2 gene segment. The competitive PCR
amplifications were performed with BV8S2- and BJ-spe-
cific primers. Run-off reactions were subsequently done
using CDR3-specific primers to reveal amplification of the
relevant sequences only. For normalization, the number of
TCR BC chain copies was determined in the same samples
using a similar procedure. Data are expressed (Fig. 4) as ra-
tio of CDR3/TCR BC mRNA copies and should corre-
spond to the frequency of individual clones bearing such
public rearrangements among all CD4 T cells. As shown in
Fig. 4 A, administration of soluble HEL results in a dose-
dependent and coordinated reduction of CDR3 copies for
Figure 3. Immunoscope analysis reveals a dose-dependent loss of pub-
lic repertoire BV8S2-J1S5HEL 107–116 in soluble HEL–induced Th2 cells.
Popliteal LNCs from mice untreated or treated with the indicated
amounts of HEL in pump were stimulated in vitro with HEL (10 mM).
(A) After 4 d, CD4 T cells were purified and subjected to RNA extrac-
tion. PCR amplification of BV8S2-BC rearrangements on cDNA and
Immunoscope analysis were then performed as described in Materials and
Methods. Data are from one representative mouse out of four analyzed
per group. (B) Data from the Immunoscope analysis were expressed as ra-
tio of the area under the public CDR3–specific peak by the sum of the
CDR3 peaks obtained in the BC-specific run-off reactions. (C) Ag-spe-
cific IFN-g and IL-4 production was measured in 72-h culture superna-
tants by ELISA. Data are expressed as mean 6 SD of four mice per group.
Results are representative of two experiments performed.
Figure 4. Soluble Ag administration induces anergy in
public clones specific for dominant and subdominant HEL
epitopes. CD8-depleted LNCs from mice pretreated with
the indicated doses of soluble HEL in pump were stimu-
lated in vitro as in Fig. 3. cDNA was prepared from CD4
T cells. Quantitative measurement of BV8S2-J2S7HEL 12–25
and BV8S2-J1S5HEL 107–116 mRNA copies was performed
by competitive PCR (Q-PCR) as described in Materials
and Methods. Sample variations were normalized on the
number of TCR b chain mRNA copies. (B) To quantify
public clone expansion during in vitro stimulation,
pooled, CD8-depleted LNCs from control or soluble
HEL–treated mice (150 mg in pump) were cultured with
10 mM of HEL and sampled at 48-h intervals for clonal
frequency determination. Results are representative of
three experiments performed.688 Different Origin of T Helper Type 2 Cells In Vivo
the two public rearrangements analyzed. Although both
public clones are still present in soluble Ag–induced effec-
tor T cell populations, their clonal expansion is reduced by
up to 90% for the highest dose of soluble Ag administered
as compared with untreated mice. These data are in agree-
ment with the Immunoscope analysis and demonstrate that
soluble Ag administration results in a reduced expansion of
public T cell clones specific for dominant and subdominant
HEL determinants. BV8S2-J1S5HEL 107–116– and BV8S2-
J2S7HEL 12–25–specific products were barely detectable in
resting splenic CD4 T cells or in CD4 T cells from mice
immunized with CFA alone and represented a frequency of
z1026 (not shown).
To determine whether the mechanism(s) of clonal unre-
sponsiveness in public CD4 T cells involved clonal anergy
or lack of recruitment in vivo, we measured their fre-
quency between days 0 and 6 after HEL restimulation in
vitro. As shown in Fig. 4 B, the rearranged public CDR3
BV8S2-J1S5HEL 107–116 and BV8S2-J2S7HEL 12–25 are de-
tected in LN CD4 T cells from HEL–CFA-immunized
control and soluble Ag–treated mice at quite similar fre-
quencies. In some experiments, BV8S2-J1S5HEL 107–116 and
BV8S2-J2S7HEL 12–25 public clones were less frequent (two-
fold reduction) than in control mice, but this was inconsis-
tently observed (not shown). HEL stimulation in vitro in-
duces the expansion of public clones (up to 10-fold) in
CD4 T cells from control mice. Conversely, the frequency
of BV8S2-J1S5HEL 107–116 and BV8S2-J2S7HEL 12–25 CD4 T
cells that are recruited in immune LNs of soluble Ag–
treated mice increases moderately over time, indicating that
public clones have an impaired capacity to proliferate in
vitro. Taken together, these data suggest that systemic Ag
administration might induce a state of functional unrespon-
siveness in public clones, correlated with the inability of
HEL-reactive CD4 T cells to produce IL-2 (14) and IFN-g
(Fig. 1 and Fig. 3 B). Indeed, analysis of intracellular Th1-
type cytokine synthesis in secondary T cells shows that the
frequency of T cells able to secrete IFN-g alone or in asso-
ciation with IL-2 is strongly inhibited in soluble HEL–
treated mice (not shown).
The Development of BV8S2-J1S5HEL 107–116 and BV8S2-
J2S7HEL 12–25 Public Clones Is Selectively Impaired in Soluble
Ag–induced But Not IFA-induced Th2 Cells. The inability
of public CDR3 CD4 T cells to differentiate toward the
Th2 phenotype after soluble protein challenge could be ex-
plained by the fact that these populations are precommitted
to develop toward the Th1 phenotype. Alternatively, the
mode of protein Ag administration (e.g., localized delivery
with adjuvant versus systemic soluble Ag release) might be
critical in selecting a particular T cell repertoire and its as-
sociated Th phenotype. To address this issue, we next
tested whether cells expressing the Th1-associated public
repertoire could be induced to develop along the Th2
pathway using IFA, which has been shown to induce Th2
cell development (28). Data in Fig. 5 A show that after ad-
ministration of HEL–IFA, CD4 T cells secrete a mixed cy-
tokine profile upon primary in vitro stimulation. In con-
trast to HEL–CFA-primed mice, secondary T cells from
HEL–IFA-immunized animals secrete low levels of IFN-g
and high levels of IL-4 (Fig. 5 B). These data are confirmed
by the analysis of intracellular cytokine synthesis in cells re-
stimulated by PMA/ionomycin after the primary culture
(Fig. 5 D). CD4 T cells from IFA-primed mice are com-
posed of a mixed population of cells that selectively secrete
either IFN-g (11%) or IL-4 (15%). In contrast, T cells from
CFA-primed mice primarily express IFN-g (18%). Analysis
of public clone size was next performed in CD4 T cells that
were stimulated with HEL for 4 d (Fig. 5 C). BV8S2-
Figure 5. Public clones expand after immuniza-
tion in CFA or IFA, but not in soluble Ag–treated
mice. CD8-depleted LNCs from mice pretreated
or not with soluble HEL and immunized with
CFA or IFA were restimulated with HEL in vitro.
(A) Ag-specific IFN-g and IL-4 production was
measured by ELISA in 72-h supernatant. (B) At
day 6, CD4 T cells (105 cells per well) were re-
stimulated with 10 mM of HEL and irradiated
syngeneic spleen cells (3 3 105 cells per well). Cy-
tokine production was analyzed by ELISA after
48 h. (C) At day 4, mRNA was extracted from
purified CD4 T cells and reverse transcribed. Pub-
lic clone frequency was determined by Q-PCR
on cDNA. (D) Secondary CD4 T cells were stim-
ulated with PMA/ionomycin, and intracellular
synthesis of indicated cytokines was analyzed as in
Fig. 1. Data are expressed as mean 6 SD of three
mice per group. Results are representative of three
experiments performed. 689 Foucras et al.
J1S5HEL 107–116– and BV8S2-J2S7HEL 12–25–bearing CD4 T
cells expand to a quite similar extent in mice primed with
HEL–CFA or HEL–IFA.
Conversely, continuous administration of soluble HEL
induces strong Th2 cell development in mice subsequently
challenged with Ag emulsified in either CFA or IFA (Fig.
5). IL-4 production by primary and secondary CD4 T cells
is always higher in soluble HEL–treated as compared with
IFA-injected mice. Quantification of the clonal size of
public CDR3 BV8S2-J1S5HEL 107–116 and BV8S2-J2S7HEL
12–25 indicates that the continuous administration of soluble
Ag induces a strong reduction in public clone size that is
independent of the type of adjuvant used for in vivo chal-
lenge (Fig. 5 C).
As shown above, selective expansion of IL-4–producing
Th2 cells in HEL–IFA-primed mice is associated with the
persistence of cells secreting IFN-g. To demonstrate that
public CDR3 BV8S2-J1S5HEL 107–116– and BV8S2-J2S7HEL
12–25–bearing cells are present in IFA-induced Th2 cells, we
compared the expression of public CDR3 on CD4 T cells
sorted according to the intracellular expression of IL-4 and
IFN-g. IFN-g1IL-42 CD4 T cells from mice immunized
with HEL–CFA were sorted as in Fig. 2. The mixed popu-
lation obtained from HEL–IFA-immune LNCs was sorted
into IFN-g2IL-41 as shown in Fig. 6 A. The expression of
the public CDR3 was analyzed at the DNA level by com-
petitive PCR as described in Fig. 4. Data in Fig. 6 B dem-
onstrate that IL-4–producing cells that expand in CD4 T
cells from HEL–IFA-immune LNCs contain the BV8S2-
J1S5HEL 107–116 and BV8S2-J2S7HEL 12–25 public clones with
a frequency similar to that of INF-g–producing cells from
HEL–CFA-immune LNCs. These data demonstrate that
these two types of adjuvant induce different Th phenotype
acquisition in the same precursor population, indicating
that HEL-specific CD4 T cells that express the public rear-
rangement are not precommitted to the Th1 phenotype.
Discussion
In this paper, we have examined the origin of Th2 cells
induced in BALB/c mice after chronic administration of
low-dose soluble Ag. We have studied the CD4 T cell re-
sponses to dominant and subdominant HEL epitopes for
which public rearrangements of TCR b chain have been
characterized (16, 17). At least two models could explain
the effect of continuous administration of soluble protein in
the selective development of Th2 cells. According to the
first one, soluble Ag administration induces clonal devia-
tion from the Th1 to the Th2 phenotype. Thus, systemic
Ag presentation results in T cell priming but fails to induce
IL-12, so that in the absence of this cytokine and in the
presence of IL-4, the majority of HEL-reactive T cells de-
velop along the Th2 pathway. The alternative model in-
volves two populations of precursor cells that are differen-
tially affected after soluble HEL administration. In this case,
the dominant repertoire that normally expands after prim-
ing with Ag in adjuvant is rendered unresponsive after
soluble Ag delivery. Concomitantly, this mode of Ag ad-
ministration selectively induces different precursor T cell
populations to develop along the Th2 pathway. Previous
experiments have suggested that Th1 inhibition and Th2
priming by continuous delivery of soluble Ag were two in-
dependent mechanisms. For instance, Ag-specific Th2 cell
development was observed in genetically predisposed mice,
whereas Th1 cell development was blocked in any mouse
strain tested (15). In addition, blocking Th2 cell develop-
ment in BALB/c mice did not reverse the unresponsiveness
in Th1 cells, indicating that these two phenomena may oc-
cur independently in the same mouse strain (14). Data in
the present paper indeed support this hypothesis and pro-
vide direct evidence that soluble Ag–induced Th2 cell de-
velopment is not due to clonal deviation, suggesting that in
this model, effector Th cell populations rather originate
from different precursors in vivo.
We directly demonstrate that the two public rearrange-
ments BV8S2-J2S7HEL 12–25 and BV8S2-J1S5HEL 107–116 are
predominantly associated with IFN-g–producing CD41 T
cells from HEL–CFA-primed mice. As we have quantified
the number of public CDR3 clones among all TCR b
chains, and because all T cells are likely to express the same
number of TCR-b gene transcripts (29), this ratio should
correspond to the frequency of public CDR3–bearing cells
Figure 6. Public clones are recruited to a similar extent
in adjuvant-guided IFN-g– or IL-4–producing CD4 T
cells. (A) Secondary Ag–specific CD4 T cells from mice
immunized with HEL in IFA were stained intracellularly
for IFN-g and IL-4 synthesis and sorted according to their
intracytoplasmic IL-4 cytokine expression. (B) After DNA
extraction and Cb normalization, competitive PCR was
performed for the two public rearrangements with 20 or
30 copies of BV8S2-J2S7HEL 12–25and BV8S2-J1S5HEL 107–116
competitor plasmids, respectively. The DNA amount ana-
lyzed in both populations corresponded to 2 3 105 Cb
copies. Results are expressed as fluorescence intensity of
CDR3-specific run-off products corresponding to the ge-
nomic sequence (wt) and competitor plasmid (pCDR3) as
indicated. IFN-g–sorted CD4 T cells from HEL–CFA-
primed mice were prepared as described in Fig. 2.690 Different Origin of T Helper Type 2 Cells In Vivo
among all CD4 T cells. The frequency of each public clone
was calculated to be in the range of 1025 to 0.5 3 1024 of
total helper T cells. Considering that at least 107 CD4 T
cells are recruited in popliteal immune LNs (23), it means
that for each public rearrangement, up to 500 CD4 T cells
expressing a unique CDR3 sequence are present in the two
lymphoid organs 9 d after HEL priming in adjuvant, a re-
sult in agreement with previously published estimates (23).
However, higher clonal frequency of Ag-specific T cells in
immune LNs has been reported by others (30, 31). Several
reasons could explain this discrepancy. We have analyzed
single TCR b chain rearrangements expressed most likely
in individual T cell clones, because at least BV8S2-J2S7HEL
12–25 T cells express an AV-J public rearrangement with a
conserved CDR3 motif (17). In addition, 5 to 10 times
more Ag in a different type of adjuvant was used in the
other studies (30, 31). This difference could easily account
for the higher number of Ag-specific T cell expansions ob-
served (30, 31).
The clonal frequency of public clones in CD4 T cells
from normal spleen or CFA-primed immune LNs was de-
tectable but below 1026. The quantification of the two
public rearrangements, BV8S2-J2S7HEL 12–25 and BV8S2-
J1S5HEL 107–116, was highly specific to HEL priming and re-
vealed a high frequency of 1–4 3 1024 after HEL restimu-
lation in vitro. As public CDR3 clones are found almost
exclusively in IFN-g1 cells that represent z20% of CD4 T
cells, the frequency of public clones in IFN-g–secreting ef-
fector T cells can be estimated at 0.2% for each public rear-
rangement. Indeed, by quantitating the frequency of public
CDR3 among TCR b chain DNA copies on IFN-g–
sorted cells, we calculated that each public clone tested rep-
resents 0.1–0.2% of Th1 effector cells (data not shown).
The data presented here indicate that the expansion
of BV8S2-J2S7HEL 12–25 and BV8S2-J1S5HEL 107–116 public
clones in vivo required Ag administration in adjuvant but
not in soluble form, and that the type of adjuvant (CFA
versus IFA) can influence the polarization of Ag-specific ef-
fector T cells. In agreement with recent work (32), priming
in IFA, unlike CFA, promotes CD4 T cell development
toward a mixed population of IFN-g– or IL-4–secreting
cells. This is not likely to involve qualitative differences in
the APCs involved in Ag presentation in vivo, as we have
previously shown that dendritic cells (DCs) isolated from
immune LNCs of both IFA- and CFA-primed mice are the
main APC type expressing peptide–class II complexes (33).
Most likely the microbial products present in CFA could
act in two ways: (a) by directly inducing IL-12 production
by DCs (34) and (b) by stimulating a high frequency of
mycobacterium-specific T cells that would in turn activate
DCs to secrete IL-12 through CD40–CD40L interactions
favoring the development of IFN-g–producing Ag–specific
CD4 T cells (35). The net result of the increased produc-
tion of these two cytokines would be to maintain IL-12R
b2 subunit expression on T cells and their subsequent de-
velopment toward a stable Th1 phenotype (36, 37). Con-
versely, BALB/c T cells activated in a less inflammatory
environment (IFA) may rapidly lose their capacity to re-
spond to IL-12 signaling (38), favoring the expansion of
Ag-specific CD4 T cells with a Th2 phenotype. Taken to-
gether, our data demonstrate that public clones specific for
dominant and subdominant HEL determinants are re-
cruited by both types of adjuvant in vivo and differentiate
toward type 1 or type 2 effector T cells. Thus, CD4 T cells
expressing these two public repertoires are not precommit-
ted to Th1 development and probably derive from naive
precursors that have the capacity to develop toward either
IFN-g– or IL-4–producing cells depending on the pres-
ence of mycobacterium products in the Ag depot.
Analysis of T cell anergy in vivo has relied so far on
transgenic models in which a large number of T cells bear-
ing the same TCR are exposed to high concentrations of
soluble Ag (39, 40). Although this enables the tracking of
the fate of clonotype-bearing T cells, the possibility of ex-
trapolating these data to normal T cell populations has not
been addressed. Our data are the first to analyze the mech-
anisms involved in soluble Ag–induced unresponsiveness in
normal CD4 T cells in vivo. Preadministration of the solu-
ble protein results in a strong decrease (up to 90%) of the
Th1-associated CDR3 motifs in HEL-specific Th2 cells, as
detected by quantitative PCR–based analysis. The loss of
public CDR3 is not due to peripheral deletion or activa-
tion-induced cell death but rather appears to result from
the induction of T cell anergy. Indeed, we show that al-
though public CDR3–bearing T cells are present in im-
mune LNCs from soluble Ag–treated mice, they poorly
proliferate after in vitro challenge. Furthermore, the coor-
dinated reduction in the size of BV8S2-J2S7HEL 12–25 and
BV8S2-J1S5HEL 107–116 T cell clones correlates with the de-
creased production of IL-2 and IFN-g by HEL-reactive
CD4 T cells (14) and is dependent on the dose of soluble
Ag administered. These data support the hypothesis that
systemic Ag administration can induce tolerance in normal
T cell populations in vivo by a mechanism resembling
clonal anergy, similar to what has been shown in a TCR-
transgenic adoptive transfer system (41, 42). Although Th2
cells obtained from mice pretreated with soluble HEL can
produce IL-4 in response to the 12–25 and 103–117
epitopes, the frequency of public BV8S2-J2S7HEL 12–25– and
BV8S2-J1S5HEL 107–116–bearing cells is strongly reduced in
this T cell population as compared with Th1-type cells ob-
tained from HEL–CFA-primed mice. Regardless of the ex-
act mechanism involved, our data show that continuous re-
lease of soluble Ag induces effective reduction of the clonal
size of public CD4 T cells specific to dominant and sub-
dominant determinant of the protein. Therefore, the strong
development of Th2-like memory cells induced by this
mode of Ag administration is not due to a massive immune
deviation of the dominant public repertoires toward the
Th2 pathway.
The unexpected feature of the data presented in this pa-
per is the demonstration that soluble Ag administration in
vivo can simultaneously induce tolerance in some precur-
sor T cells and probably prime for Th2 development a dif-
ferent pool of precursor cells in susceptible mouse strains.
How can this selectively be achieved? What is the mecha-691 Foucras et al.
nism that controls whether, after ligand–TCR interactions,
two different outcomes may ensue tolerance or activation?
One possible explanation is that differences in TCR affinity
between the two precursor populations could contribute to
the differential effect of soluble Ag administration. Indeed,
several reports have demonstrated that the development to-
ward the Th1 or Th2 phenotype of the same TCR-trans-
genic T cells can be regulated by varying the signal strength
of an antigenic peptide during the initial phase of T cell
priming in a neutral environment (43–45). This has been
achieved by using altered peptide ligands (45) or by varying
the density of epitopes presented by APCs (43, 44). In our
model, Th1 and soluble Ag–induced Th2 cells at least share
similar specificity: they both recognize epitopes contained
in the HEL sequences 12–25 and 103–117. It is therefore
tempting to speculate that after soluble Ag priming, a dif-
ferent TCR repertoire has been selected with a lower affin-
ity for its ligand and/or with a difference in fine epitopic
specificity (46). Conversely, the public clones that are in-
duced when Ag is administered in adjuvant are likely to
harbor high-affinity TCRs. Systemic Ag presentation may
favor engagement of the inhibitory receptor for B7 mole-
cules, CTLA-4, that has been shown to result, in the ab-
sence of IL-12, in the induction of functional T cell inacti-
vation (42). Only high-affinity T cell clones would be
sensitive to such a mechanism in vivo. Alternatively, it is
possible that this mode of chronic Ag administration might
favor the presentation of cryptic determinants by a re-
stricted population of APCs, such as CD8a2 DCs (47). Se-
lective Ag presentation by this professional APC would di-
rect the development of CD4 T cells specific for these
cryptic epitopes toward the Th2 pathway. Whatever the
origin and specificity of soluble Ag–induced memory Th2
cells, their initial phase of differentiation is highly sensitive
to the presence of proinflammatory cytokines in the mi-
croenvironment, as IL-12 coadministration results in an
unipolar Th1 response in this model (37).
In conclusion, our study support the hypothesis that the
mode of Ag administration may determine specific reper-
toire selection in effector CD4 T cells in vivo. Systemic Ag
presentation in the absence of proinflammatory signals,
such as IL-12, results in the selective priming of a specific
CD4 T cell population that develop along the Th2 path-
way in genetically predisposed mouse strains. The polariza-
tion toward the Th2 phenotype induced by soluble protein
administration appears to be controlled by a balance be-
tween priming of Th2 precursor populations on the one
hand and induction of functional unresponsiveness in the
Th1 precursor populations on the other. Furthermore, we
show that the clonal size of T cells expressing the two pub-
lic CDR3 motifs is effectively reduced in soluble HEL–
induced, IL-4–producing CD41 T cells but not in Th2 cells
that develop after Ag priming in IFA. Therefore, we pro-
vide direct evidence that the induction of Th2 cell devel-
opment by chronic antigenic stimulation is not due to large
scale clonal deviation, indicating that IL-4–producing CD4
T cells may arise from a different pool of precursor cells de-
pending on the conditions of Ag exposure in vivo. Under-
standing the cellular and molecular basis that drive the se-
lective expansion of Th2 cells in this model system should
have important implications in our comprehension of the
genetic factors that influence the differentiation of distinct
Th cell subsets in predisposed hosts in vivo.
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